- Five Prime Therapeutics (NASDAQ:FPRX) presents the first preclinical data from its anti-CCR8 FPA157 program at The SITC 2020.
- CCR8 expression is highly restricted to T regulatory (Treg) cells within the tumor.
- Preclinical studies demonstrate that FPA157 depletes CCR8+ Tregs in the tumor microenvironment while sparing peripheral Treg subsets.
- Anti-CCR8 treatment elicits the development of robust anti-tumor memory responses.
- FPA157 leads to potent natural killer (NK) cell-dependent killing of CCR8+ target cells.
- FPT157 is undergoing IND-enabling studies
- https://seekingalpha.com/news/3635383-five-prime-shares-rise-14-anti-ccr8-antibody-fpa157-shows-promising-effect
Thursday, November 12, 2020
Five Prime shares rise as anti-CCR8 antibody FPA157 shows promising effect
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.